Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
We examined the effects of interferon (IFN)beta-1a on interleukin (IL)-12p70 and IL-10 secretion in 27 Relapsing Remitting Multiple Sclerosis (RRMS) patients, divided in responders and non-responders. In responders, IFNbeta-1a does not change the IL-12p70 concentrations, but it leads to a remarkable increase in the IL-10 production. Besides, a high IL-10/IL-12 ratio is demonstrated during the first six months of therapy. In non-responders, there were not significant alterations in the cytokine profile. We suggest that IFNbeta-1a effect in RRMS patients could be explained by its modifying effect on cytokine pattern. Moreover, we propose a possible role of IL-10/IL-12 ratio as a serum marker predictive of favorable clinical course.
Carrieri
Pietro B
PB
Department of Neurological Sciences, University of Naples Federico II, Italy. pbcarrieri@libero.it
Ladogana
Paolo
P
Di Spigna
Gaetano
G
de Leva
Maria Fulvia
MF
Petracca
Maria
M
Montella
Silvana
S
Buonavolontà
Luigi
L
Florio
Ciro
C
Postiglione
Loredana
L
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002478:Cells, Cultured; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000096:biosynthesis*; D018664:Interleukin-12 / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D015854:Up-Regulation / Q000276:immunology
D015415:Biomarkers; C508609:IL10 protein, human; D016753:Interleukin-10; D018664:Interleukin-12; D016899:Interferon-beta; D000068556:Interferon beta-1a